Monday, October 5, 2026
EnglishEnglishРусскийEspañolFrançaisPortuguêsالعربية
The Global WireHorizon Global News

Credited outlet

Jason Mast

1 story written by The Global Wire newsroom from reporting first published by Jason Mast. Full credit for the original reporting belongs to them.

Visit Jason Mast →

Stories credited to Jason Mast

Vaxcyte Phase 3 Pneumococcal Vaccine Trial Meets Primary Endpoints, Threatening Pfizer and Merck
HealthSource: Jason Mast

Vaxcyte Phase 3 Pneumococcal Vaccine Trial Meets Primary Endpoints, Threatening Pfizer and Merck

Clinical-stage biotech Vaxcyte announced positive Phase 3 results for its experimental pneumococcal vaccine, setting up a commercial battle with industry leaders Pfizer and Merck.